NEXGEL, INC.
Close on Oct 19, 2026
- Market cap
- $52.28M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | Before market open | $3.69M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $2.93M | $-0.08 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $2.88M | $-0.09 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $2.81M | $-0.09 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $2.94M | $-0.11 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | $1.44M | $-0.14 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | Before market open | $1.10M | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 12, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | 2025 | $13.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Nexgel filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Appoints Ian Blackman as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
NEXGEL Signs Definitive Agreement to License
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Spin-Off of Drug Delivery Program into NexGelRx
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
NEXGEL Appoints Chief Accounting Officer of
Executive or director change · Other events · EX-99.1 to Form 8-K
Announces $950,000 Registered Direct Offering and Concurrent Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
and STADA AG Announce Expansion of Partnership for North America
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Record Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Issues Letter to Shareholders and Provides Guidance for 2024 and 2025
Results of operations · EX-99.1 to Form 8-K
Appoints Joseph F. McGuire as Chief Financial Officer
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Results of operations · EX-99.1 to Form 8-K
Announces $2,000,000 Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Preannounces Expected Record Third Quarter 2024 Revenue of
Results of operations · EX-99.1 to Form 8-K
Reports Record Second Quarter 2024 Revenue of $1.44 Million
Results of operations · EX-99.1 to Form 8-K
Announces $1,110,000 Registered Direct Offering Led by Insiders
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of
Results of operations · EX-99.1 to Form 8-K
Acquires International Beauty Brand, Silly George
Material agreement · Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year
Results of operations · EX-99.1 to Form 8-K
Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Results of operations · EX-99.1 to Form 8-K
Announces $975,000 Registered Direct Offering Led by Insiders
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
Regulation FD disclosure · EX-99.1 to Form 8-K
Acquires Kenkoderm Psoriasis Skincare Line
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
Results of operations · EX-99.1 to Form 8-K
NEXGEL Secures Supply Agreement with AbbVie
Regulation FD disclosure · EX-99.1 to Form 8-K